Literature DB >> 26039202

Improving the clinical outcome of unmanipulated haploidentical blood and marrow transplantation.

Y-J Chang1, X-J Huang2.   

Abstract

Unmanipulated haploidentical blood and marrow transplantation (HBMT) has been one of the most applied haploidentical transplant protocol, which offers rapid immune recovery, desirable health-related quality of life and comparable survival rate with those who received HLA-identical sibling transplantation or HLA-matched unrelated donor transplantation. Compared with HLA-identical sibling recipients, HBMT recipients experienced a lower risk of late effects. The HBMT protocol also shows superior in treating pediatric hematological malignancies compared with umbilical cord blood transplantation and could be successfully used as a post-remission treatment algorithm for adults acute myeloid leukemia with unfavorable cytogenetics. Several approaches, including optimal dose investigation of anti-thymocyte globulin, selecting the best donor, and modified donor lymphocyte infusion, have been designed to improve transplant outcomes.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26039202     DOI： 10.1038/bmt.2015.90

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  20 in total

1.  Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation.

Authors:  Yuan Kong; Ying-Jun Chang; Ya-Zhe Wang; Yu-Hong Chen; Wei Han; Yu Wang; Yu-Qian Sun; Chen-Hua Yan; Feng-Rong Wang; Yan-Rong Liu; Lan-Ping Xu; Dai-Hong Liu; Xiao-Jun Huang
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-20       Impact factor: 5.742

Review 2.  Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

3.  Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.

Authors:  Chen-Hua Yan; Dai-Hong Liu; Lan-Ping Xu; Kai-Yan Liu; Ting Zhao; Yu Wang; Huan Chen; Yu-Hong Chen; Wei Han; Xiao-Jun Huang
Journal:  Clin Transplant       Date:  2012-03-20       Impact factor: 2.863

Review 4.  Immune reconstitution after haploidentical hematopoietic stem cell transplantation.

Authors:  Ying-Jun Chang; Xiao-Yu Zhao; Xiao-Jun Huang
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-04       Impact factor: 5.742

5.  A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia.

Authors:  L P Xu; K Y Liu; D H Liu; W Han; H Chen; Y H Chen; X H Zhang; Y Wang; F R Wang; J Z Wang; X J Huang
Journal:  Bone Marrow Transplant       Date:  2012-05-28       Impact factor: 5.483

6.  Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT.

Authors:  X-D Mo; L-P Xu; D-H Liu; Y-H Chen; W Han; X-H Zhang; H Chen; Y Wang; J-Z Wang; K-Y Liu; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2012-01-09       Impact factor: 5.483

7.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

Authors:  Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

Review 8.  Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts.

Authors:  Ying-Jun Chang; Xiao-Jun Huang
Journal:  Curr Opin Hematol       Date:  2012-11       Impact factor: 3.284

9.  Nonmalignant late effects in survivors of partially matched donor hematopoietic stem cell transplantation.

Authors:  Xiao-Dong Mo; Lan-Ping Xu; Dai-Hong Liu; Xiao-Hui Zhang; Huan Chen; Yu-Hong Chen; Wei Han; Yu Wang; Feng-Rong Wang; Jing-Zhi Wang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-05       Impact factor: 5.742

10.  Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide.

Authors:  Luca Castagna; Roberto Crocchiolo; Sabine Furst; Stefania Bramanti; Jean El Cheikh; Barbara Sarina; Angela Granata; Elisa Mauro; Catherine Faucher; Bilal Mohty; Samia Harbi; Christian Chabannon; Carmelo Carlo-Stella; Armando Santoro; Didier Blaise
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-13       Impact factor: 5.742
View more
  4 in total

Review 1.  Haploidentical Bone Marrow Transplantation in 2015 and Beyond.

Authors:  Guillermo J Ruiz-Argüelles; Guillermo J Ruiz-Delgado; Oscar González-Llano; David Gómez-Almaguer
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

Review 2.  Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents.

Authors:  Ho Joon Im; Kyung-Nam Koh; Jong Jin Seo
Journal:  Blood Res       Date:  2016-03-25

3.  [Advances in haploidentical hematopoietic stem cell transplantation for myelodysplastic syndromes].

Authors:  Y Wang; X J Huang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

Review 4.  Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Xiao-Jun Huang
Journal:  Front Immunol       Date:  2019-11-01       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.